Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific... – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-08-01
2006-08-01
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
Bacterium or component thereof or substance produced by said...
C424S279100, C424S278100, C424S234100, C424S248100, C514S866000, C514S008100, C514S012200
Reexamination Certificate
active
07083798
ABSTRACT:
The present invention relates generally to a method of immunomodulating therapy and pharmaceutical compositions useful for same. More particularly, the present invention provides a method of ameliorating the effects of autoimmune conditions. Even more particularly, the present invention contemplates a method for preventing, delaying onset of or otherwise ameliorating the effects of insulin-dependant diabetes mellitus (IDDM) by administering a cell wall subunit or a chemical or functional equivalent thereof fromMycobacteriumor a related organism or other suitable biological source. The present invention is further directed to a pharmaceutical composition useful in preventing, delaying onset of, curing, curing in association with islet replacement or otherwise ameliorating the effects of autoimmune conditions such as IDDM or for enhancing an immune response against melanoma or other cancer comprising a cell wall subunit or a chemical or functional equivalent thereof fromMycobacteriumor a related organism or other suitable biological source. The cell wall subunit is preferably mycolyl-arabinogalactan-peptidoglycan (MAPG) or a component thereof.
REFERENCES:
patent: 4152423 (1979-05-01), Adam et al.
patent: 4307229 (1981-12-01), Liav et al.
patent: 4877612 (1989-10-01), Berger et al.
patent: 2120548 (1983-12-01), None
patent: WO 85/05034 (1985-11-01), None
patent: WO-87/02249 (1987-04-01), None
patent: WO 91/02542 (1991-03-01), None
patent: WO-94/16727 (1994-08-01), None
patent: WO-96/00579 (1996-01-01), None
patent: WO-96/26288 (1996-08-01), None
Qin et al J Immunol. 150 (5), 2072-80, 1993.
Robinson et al J Clin Lab Immunol. 24 (4), 171-6, 1987.
Stosic-Grujicic et al. Mikrobiolojija 33 (1): 27-36, 1996.
Chugh et al. Folia Microbiol. 37: 407-412, 1992.
Hirschfield et al. (Feb. 1990) “Peptidoglycan-Associated Polypeptides of Mycobacterium Tuberculosis,”J. Bacteriol. 172(2): 1005-1013.
Azuma et al. (Nov. 1968) “Fractionation of Mycobacterial Cell Wall,”J. Bacteriol. 96(5): 1885-1887.
Baxter et al. (1994) “Mycobacteria Precipitate an SLE-like Syndrome in Diabetes-Prone NOD Mice,”Immunology83: 227-231.
Sadelain et al. (May 1990) “Prevention of Type I Diabetes in NOD Mice by Adjuvant Immunotherapy,”Diabetes39(5), 583-587.
Harada et al. (1990) “Prevention of Overt Diabetes and Insolitis in NOD Mice by a Single BCG Vaccination,”Diabetes Res. Clin. Pract.8: 85-89.
Beaudet et al. (1983) “Stimulation of Non-Specific Anti-Tumor Resistance in the Mouse Using Cell Wall Preparations from Four BCG Substrains,”Ann. Immunol. (Paris)134C(2): 215-226.
Dockrell et al. (Oct. 1996) “Induction of Th1 Cytokine Responses by Mycobacterial Antigens in Leprosy,”Infect. Immun.64(10): 4358-4389.
McNeil et al. (Oct. 1996) “Evidence for the Nature of the Link Between the Arabinogalactan and Peptidoglycan of Mycobacterial Cell Walls,”J. Biol. Chem.265(30): 18200-18206.
Barnes et al. (Apr. 1992) “Tumour Necrosis Factor Production in Patient with Leprosy,” Infect. Immun. 60(4): 1441-1446.
Hayashi, Akira (1994) “Interferon-y as a Marker for the Effective Cancer Immunotherapy with BCG-Cell Wall Skeleton,”Proc. Japan Acad70(10): 205-209.
Chin et al. (1996) “Mycobacterium Cell Wall: An Alternative to Intravesical Bacillus Calmette Guerin (BCG) Therapy in Orthotopic Murine Bladder Cancer,”Journal of Urology156: 1189-1193.
Morales et al. (May 1995) “Immunotherapy of an Experimental Adenocarcinoma of the Prostate,”Journal of Urology153: 1706-1710.
Gray et al. (1975) “Brief Communication: Immunotherapy of Cancer: Tumor Suppression And Regression by Cell Walls of Mycobacterium Phiel Attached to Oil Droplets,”Journal of the National Cancer Institute55(3): 727-730.
Schultz et al. (1995) “Effect of DETOX as an Adjuvant for melanoma Vaccine,” Vaccine 13(5): 503-508.
Shehadah et al. (Mar. 1994) “Effect of Adjuvant Therapy on Development of Diabetes in Mouse and Man,”The Lancet343: 706-707.
Gazda et al. (Oct. 1996) “Regulation of Autoimmune Diabetes: Characteristics of Non-Islet-Antigen Specific Therapies,”Immunology and Cell Biology74(5): 401-407.
Partial European Search Report directed to Counterpart EP Application No. 97911956.
European Office Action mailed Feb. 2, 2006, directed to counterpart EP Application No. 97911956.7
Centenary Institute of Cancer Medicine and Cell Biology
Devi S.
Morrison & Foerster / LLP
LandOfFree
Method of immunomodulatory treatment of insulin dependent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of immunomodulatory treatment of insulin dependent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of immunomodulatory treatment of insulin dependent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3698816